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Abstract
Background: The majority of patients suffering from chronic health disabilities is beyond 70 years of age. Typical
late-onset chronic diseases include those affecting the heart, the kidney, cancer, and conditions of the eye such as
age-related macular degeneration. These diseases disable patients for many years and largely compromise autonomy
in daily life. Due to challenges in recruiting the elderly, the collection of population-based epidemiological data as a
prerequisite to understand associated risk factors and mechanisms is commonly done in the general population within
an age-range of 20 to 70 years.
Methods/Design: We establish the German AugUR study (Age-related diseases: understanding genetic and
non-genetic influences - a study at the University of Regensburg), a prospective study in the mobile elderly
general population in and around Regensburg in eastern Bavaria. In the long term, we aim to recruit 3,000
persons of Caucasian ethnicity with at least 70 years of age via residents’ registration offices and conduct
3-year follow-ups.
The study protocol includes a standardized interview regarding social and life-style factors, medication history,
quality-of-life, and existing diagnoses of common diseases. The participants undergo medical examinations
for ophthalmological, cardiovascular or diabetes-related conditions, and general measurements of body shape
and fitness. The program is particularly tailored for the elderly. Biobanking of whole blood, serum, plasma,
and urine is conducted and standard laboratory measurements are performed in fresh samples.
Discussion: AugUR is specifically designed as a research platform to host studies of late onset diseases. Consequently,
this platform will help (1) to unravel the genetic and non-genetic etiology of disease development and progression,
(2) to serve as control group of elderly individuals for comparisons with various patient groups, (3) to derive prevalence
and incidence data on chronic diseases, and (4) to provide clinical reference parameters for the elderly mobile general
population. This data will foster our understanding of disease mechanisms, which may ultimately help to improve
prevention, diagnosis, and therapy for frequent chronic diseases. Here we present the baseline study protocol of AugUR.
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Background
A major proportion of hospitalized patients is above
70 years of age. This is mainly due to a variety of chronic
diseases that tend to occur later in life and disable the eld-
erly patients for many years or even decades. Such diseases
include type 2 diabetes [1], cancer [2], cardiovascular com-
plications [3], and eye diseases like age-related macular
degeneration (AMD) [4], the leading cause of blindness in
the elderly.
Morbidity and disability at high age do not only affect
individuals’ quality of life, but also impact upon public
health care systems. Such challenges will increase given
demographic changes towards a growing proportion of
persons above 80 years of age, in Europe from currently
4 to 10 % in 2050 [5]. Consequently, the number of pa-
tients with late-onset diseases will increase. Public health
efforts that help increase life expectancy also need to in-
clude measures to avoid disabling diseases.
To understand the etiology of late-onset diseases, it
is important to know their genetic architecture. Most
diseases have a genetic component with a heritability
of 40–70 % [6, 7] and numerous genetic loci identi-
fied [8, 9]. The knowledge of the genetic background
provides insights to disease mechanisms and will stimulate
ideas for new therapeutic options. Genome-wide associ-
ation studies (GWAS) have been immensely successful in
describing the genetic basis for numerous diseases [8]. To
increase statistical power and to identify even small gen-
etic effects, such analyses are conducted typically by com-
bining the results of multiple studies in meta-analyses.
Previous results from GWAS have usually been obtained
by merging studies of diverse designs, often recruited from
patient groups with limited assessment of non-genetic risk
factors, and lack of follow-up. In order to investigate the
combination of genetic and life style factors in relation to
disease incidence and progression, large population-based
prospective follow-up studies with high quality phenotyp-
ing are warranted.
Current large-scale prospective epidemiologic stud-
ies often focus on adults less than 70 years of age,
such as the German National Cohort [10] or the UK
Biobank [11]. This is due to the fact that recruiting
elderly individuals is particularly challenging regarding
the time and patience required for each step of the
study program, including walking from one room to
another, un- and re-dressing, or answering questions.
A further challenge is the impaired visual, auditory, or
cognitive function frequently encountered in elderly indi-
viduals, necessitating a study program that is tailored to
their specific conditions.
Therefore, we set out to establish a study platform using
population-based recruitment of mobile elderly individ-
uals in and around the east Bavarian city of Regensburg.
This platform will allow for harboring studies on various
late-onset common diseases using cross-sectional, case-
control, or cohort study designs.
Methods/design
Main objective and overall design
The main objective of our prospective study platform is
to build a data base that enables the investigation of gen-
etic and non-genetic risk factors as well as biomarkers
for late-onset diseases. The AugUR study (Age-related
diseases: understanding genetic and non-genetic influ-
ences - a study at the University of Regensburg) is a pro-
spective study from the general elderly population in
and around the city of Regensburg. The baseline survey
includes an in-person interview, biobanking and medical
examinations. A follow-up with a second in-person visit
after 3 years and subsequent mortality and morbidity
follow-ups are planned.
Study population and recruitment
Our study cohort consists of the mobile elderly popula-
tion at least 70 years of age. The recruitment area is the
city and county of Regensburg, which is a middle-sized
Bavarian city with ~150,000 inhabitants located in the
South-East of Germany with the next bigger cities >100
km away; the study region includes both urban and rural
areas with a total of ~330,000 inhabitants, mostly of
Caucasian ethnicity. We are aiming at 3,000 participants
during a five year recruitment period from 2013 to 2018
with subsequent follow-ups.
For the baseline survey, we obtain a random sample
from the local registries of residence. Selected inhabi-
tants are contacted by a mailed invitation letter giving
the choice to answer per phone or via a pre-paid post
card stating their phone number. Those that contact the
study center in order to raise their unwillingness to par-
ticipate are asked to complete a short phone interview
to assess the reasons for refusal, if possible. These per-
sons are not contacted again. In addition, a random subset
of non-responders undergoes a non-compliance interview
by phone.
Persons indicating their interest in participating the
study are contacted and an appointment is made. There
are no a priori exclusion criteria. Invited persons are
welcomed at the recruitment center at the University
Hospital Regensburg. Informed consent is obtained by
trained study staff, and those giving consent are sub-
jected to the study program. Participants are asked for
agreement to be re-contacted for follow-ups.
Ethic approval, data protection, and informed consent
The study protocol, study procedures, and data protection
strategy were all approved by the Ethics Committee of the
University of Regensburg, Germany (vote 12-101-0258).
Written consent is obtained according to the Declaration
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of Helsinki. Person-identifying information is strictly sepa-
rated from the study results using different computer sys-
tems and identifying numbers. Original data are stored in
a physically safe place with encrypted backup and access
limited to a restricted group of staff to ensure safety and
confidentiality. Each participant is specifically asked for
consent to be contacted in the future, to allow for genetic
analyses, and whether he/she wishes feedback regarding
their results from the physical and medical examinations
and the standard laboratory panel.
Overview of the questionnaire and the physical and
medical examinations
An in-person standardized interview and physical and
medical examinations are conducted by trained staff.
The questionnaire includes an assessment of socio-
demographic (marital status, education, profession) and
life style factors (nutrition, dietary supplements, smoking
behavior, alcohol consumption, physical activity), comor-
bidities, medication use, and quality of life. The physical
and medical examinations consist of an ophthalmological
and a cardiovascular program, measurement of diabetes-
related parameters, general fitness and anthropometry
(Table 1). Biobanking is conducted for aliquoted serum,
plasma, blood for DNA and RNA as well as urine (Table 2).
Questionnaire data and documentation of examina-
tions are initially recorded on paper and are subse-
quently transferred to an electronic case report form
(eCRF). We opted against using an ad hoc eCRF during
the interview, as we found that interaction with elderly
persons requires full eye contact and parallel entering of
information into the computer system did not yield a time
benefit, but caused a disruption of the interview. For col-
lecting and managing eCRF data, a specialized software
tool is employed (Askimed, http://www.askimed.com/).
Quality control includes monitoring the entered data by a
second independent study assistant.
Ophthalmological examination program
Overview
Interview-based ophthalmological medical history assesses
the existence, history and time of onset of major eye dis-
eases (cataract, glaucoma, diabetic retinopathy, AMD,
former ocular injury or severe infection, family history of
eye diseases) or ophthalmological interventions (eye sur-
gery, intravitreal injections, laser treatment, application of
eye drops or other eye-specific medication).
Amsler grid test and visual acuity
In order to assess irregularities in central vision, an Ams-
ler grid test is conducted according to [12]. Briefly, par-
ticipants are tested, each eye separately, with a black-on-
white Amsler grid (10×10 cm with a 0.5-cm grid) at a
reading distance of 30 cm using their most recent
reading glasses if needed and available. Participants are
instructed to fixate the black spot in the center. The test
is classified as positive when the participant claims to
see irregularities in the grid (interruptions in the net-
work of the small squares; lines are not straight and par-
allel; vibration or waving areas; gray hazed areas).
Visual acuity is the main endpoint for ophthalmo-
logical diseases. A rapid and simplified visual acuity test
is carried out on a standardized Early Treatment Dia-
betic Retinopathy Study (ETDRS)-chart for the lines
with equivalence values of 20/25 Snellen Equivalent and
20/20 Snellen Equivalent at a distance of 4 m. Study par-
ticipants use their most recent distance glasses if applic-
able. When ≥60 % letters are read correctly, the visual
acuity score is increased by +1 at 20/25 or +2 at 20/20,
respectively, for each eye separately. When <60 % letters
of 20/25 equivalence value are read correctly, the visual
acuity score per eye is -2.
Photo stress test
Dark or white adaptation time, which is the time of full
adjustment and reading ability of the eye after darkness
or very bright light, respectively, provide a psychophys-
ical assessment of retinal function [13–15]. These pa-
rameters are associated with multiple eye diseases and
are used as surrogate endpoints in clinical studies [16].
While dark adaptation requires high attention and pa-
tience of the study participants, the photo stress test to
assess white adaptation can be better applied in a stan-
dardized fashion. This strategy is the most appropriate
and clinically applicable photo-stress bleaching tech-
nique, as high intensity, long-duration bleaching mini-
mizes errors [17].
Briefly, starting with the eye with better visual acuity,
the participant´s refractive correction (if applicable) is
removed and the participant is administered to the
macular stop of a direct ophthalmoscope (Heine Beta
200 M2, Heine Optotechnik, Herrsching, Germany). The
ophthalmoscope is adjusted to full intensity, projecting
directly onto the macula for 30 s. Immediately after
bleaching, the time until the participant can read one
line less than before in the visual acuity test is measured
in seconds with refractive correction (if applicable).
Fundus camera imaging
Many eye diseases affect the retina. We thus conduct fun-
dus photography using the automatized DRS fundus cam-
era (Digital Retinography System; CenterVue, Padova,
Italy) [18]. Pictures are captured for the central and cen-
tral nasal field of the retina within a 45° view. The quality
of the fundus photographs depends on the pupil size.
Therefore, participants´ eyes are allowed to adapt in a
darkened room for 5 min before photography. Since pupil
size is known to be age-dependent [19], it is likely that
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pupils in our elderly participants are often too small to
yield a high-quality photography. Therefore, we apply a
mild mydriasis (Mydriaticum UD, pharmaSTULLN,
Stulln, Germany), when special consent is given. Par-
ticipants are explicitly informed about the consequences
of mydriasis, such as a ban on driving, and a small risk for
acute angle-closure glaucoma (1 in 20,000 to 1 in 3,000)
[20, 21]. This risk is minimized by excluding persons
from mydriasis that exhibit a flat anterior chamber, as
assessed via a portable slit lamp examination (Kowa,
Düsseldorf, Germany).
Optical coherence tomography
Comparable to ultra-sound examinations of inner organs,
the optical coherence tomography (OCT) scans the retina,
Table 1 Baseline assessment in AugUR
Category Item Instrument Method/apparatus
used
General factors Age, sex, ethnicity,
martial status
Q Interview
Education,
profession
Q Interview
Nutritional habits Q Interview
Smoking, alcohol
consumption
Q Interview
Light exposure Q Interview
Quality of life Subjective health
status, general
condition
Q Interview
Anthropometry Height, weight P Measuring station
and fitness Waist and hip
circumferences
P Measuring tape
Hand grip strength P Dynamometer
Physical activity Q Interview
Medication Current medication
intake
Q Interview
Ophthalmological Eye diseases and
eye injuries
Q/P Interview, DRS,
OCT
Phenotyping Ocular fundus P DRS, OCT
Visual acuity P ETDRS, Amsler
Cardiovascular Cardiovascular
diseases
Q Interview
Phenotyping Blood pressure,
pulse rate
P Automatic device
Ankle-brachial index P Vascular Explorer
Aortic pulse wave
velocity
P Vascular Explorer
Augmentation index P Vascular Explorer
Left/right ventricular
mass and function
P Echocardiography
Assessment of heart
valves
P Echocardiography
Diabetes History of diabetes,
diabetes medications
Q Interview
Skin
autofluorescence
P AGE reader
Serum glucose,
HbA1c
L External
laboratory
Blood parameters Blood cell count L External
laboratory
Mean corpuscular
cell volume
L External
laboratory
Mean corpuscular
hemoglobin content
L External
laboratory
Mean cellular
hemoglobin
concentration
L External
laboratory
C-reactive protein L External
laboratory
Table 1 Baseline assessment in AugUR (Continued)
LDL-, HDL-, total
cholesterol,
triglycerides
L External
laboratory
Urine parameters Albumin:Creatinine,
Protein:Creatinine
ratio
L Clinitek
Glucose, ketone,
nitrite, pH
L Clinitek
Erythrocyte and
leukocyte count
L Clinitek
Other diseases Respiratory tract
diseases
Q Interview
Kidney diseases Q Interview
Arthritic diseases Q Interview
Skin diseases Q Interview
Liver diseases Q Interview
Cancer Q Interview
Q self-reported information obtained by questionnaire, L laboratory analysis, P
physical examination, HBA1c glycated hemoglobin, LDL low-density lipoprotein,
HDL high-density lipoprotein, AGE advanced glycation end products, DRS
digital retinography system, OCT optical coherence tomography, ETDRS early
treatment diabetic retinopathy study
Table 2 Biobanking in AugUR
Origin Fraction Number of
aliquots
Storage
conditions
K3-EDTA Whole blood 6 + 4 −20 °C/-80 °C
K3-EDTA Plasma 12 + 2 −80 °C/Liquid N2
Clot
activator
Serum 12 + 2 −80 °C/Liquid N2
PAXgene RNA supernatant 2 Liquid N2
PAXgene RNA cellular
fraction
1 Liquid N2
Urine Urine supernatant 1 Liquid N2
Urine Urine with pellet 2 −80 °C
Stark et al. BMC Geriatrics  (2015) 15:130 Page 4 of 8
especially the macula and the optic disc using light. We
apply confocal scanning laser ophthalmoscopy (cSLO) and
spectral domain OCT (SD-OCT) using the SPECTRALIS
OCT Plus BluePeak (Heidelberg Engineering GmbH,
Heidelberg, Germany). This includes several views of the
retina: (i) a set of high-resolution cSLO fundus images in-
cluding infrared, blue reflectance, BluePeak autofluores-
cence as well as multicolor mode for each participants’
eye in 30° (8.7 mm) standard fovea centered view field
with 30 averaged frames by Automatic Real-Time (ART),
(ii) a set of fovea-centered SD-OCT scans (all in standard
TruTrack active eye tracking mode and with quality index
as high as possible) including one 30° (8.7 mm) horizontal
scan averaged with 100 ART, and horizontal raster pattern
scans, 20°x20° (5.8 mm x 5.8 mm), consisting of 49 sec-
tions, each averaged with 30 ART, and, additionally one
30° (8.7 mm) horizontal and vertical line, each averaged
with 100 ART in enhanced depth imaging mode, and (iii)
a circled SD-OCT scan around the optic disc with 100
ART to assess retinal nerve fiber layers.
SD-OCT scans and cSLO images are analyzed ap-
plying the Heidelberg Eye Explorer software (Heidelberg
Engineering GmbH, Heidelberg, Germany).
Cardiovascular examinations
Overview
The interview-based medical history assessment includes
the existence, history, and time of onset of cardiovascu-
lar diseases and interventions. Lipid parameters are mea-
sured in fresh blood in non-fasting condition. Fasting
before study center visit was unacceptable for our elderly
study population. In order to assess subclinical and clin-
ical cardiovascular conditions, we established an in-
depth phenotyping program including measurement of
blood pressure, pulse rate, vascular status, and imaging
by a short (for all) and an extended (for a subgroup) car-
diac ultrasound protocol as described below.
Blood pressure, pulse and vascular phenotyping
Blood pressure and pulse rate are measured using an
automatic device (Omron M10-IT; Omron Healthcare
Co Ltd., Kyoto, Japan) after 5 min of resting time. Blood
pressure is measured three times and the average of the
second and third measurement is determined. Ankle-
brachial index, aortic pulse wave velocity and augmenta-
tion index are derived from the Vascular Explorer system
(Enverdis GmbH medical solutions, Jena, Germany).
Echocardiography
The echocardiographic measurements are intended to
provide established and reliable parameters of the
morphology and function of the heart chambers and
valves. We use a commercially available ultrasound unit
(HP Sonos 5500 with 2–4 MHz probe; Philips,
Eindhoven, The Netherlands) and implement the recom-
mendations of the European Association of Echocardi-
ography for clinical trials [22]. Each measurement is
repeated three to ten times according to protocol to re-
duce random error. The stored tracings are assessed post
hoc using analytical software Xcelera R3.2 L1 Version
3.2.1.520 – 2011 (Philips, Eindhoven, The Netherlands).
We established a short and an extended protocol.
The short echocardiographic program focuses on left
ventricular function and the morphology of the four
heart chambers accounting for chamber-specific car-
diac remodeling processes [23]. Cardiac morphology in-
cluding areas and volumes of the four heart chambers
determined in the apical four- and two-chamber views as
well as left ventricular dimensions assessed by two-
dimensional guided M-mode in the left parasternal long
axis view are recorded [24]. The left ventricular mass is
calculated by the Devereux formula [25]. For functional
evaluation, left ventricular systolic function is deter-
mined by the ejection fraction estimated by the modi-
fied Simpson’s method [24]. Diastolic function is
assessed by pulse wave Doppler measurement of the
transmitral flow profile and pulsed tissue Doppler assess-
ment of the diastolic mitral annular velocity as described
previously [26] and recommended by the American Soci-
ety of Echocardiography [27]. This program is performed
by a study nurse who was trained at the Cardiology Clinic
of the University Hospital Regensburg and has conducted
more than 300 echocardiographic examinations before
starting to examine without supervision.
For a subgroup of participants, we conduct an ex-
tended echocardiographic program additionally assessing
right ventricular function and the heart valves performed
by an experienced cardiology-trained physician. The fol-
lowing parameters are determined: right ventricular
function is estimated by tricuspid annular plane systolic
excursion and the Tei-Index calculated by tissue Doppler
imaging [28]. For an assessment of the heart valves,
transvalvular flow profiles are acquired [29].
Assessment of diabetes-related parameters, anthropometry
and general fitness
Information about previous diagnosis of diabetes and
diabetes therapy are obtained at the interview. HbA1c
and glucose measurements are conducted in fresh blood.
In order to derive a marker for diabetes and cardiovascu-
lar risk [30], we assess skin autofluorescence to measure
advanced glycation end products (AGE) using the AGE
Reader SU (DiagnOptics, Groningen, The Netherlands).
Anthropometric measurements are carried out follow-
ing the World Health Organization recommendations
[31]. Height and weight (using a Seca measuring station
285; Seca, Hamburg, Germany) as well as waist and hip
circumference (using a measuring tape) are measured in
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standing position with light clothing to the nearest
0.5 cm (height, waist and hip circumference) and the
nearest 0.1 kg (weight).
General fitness is assessed using hand grip strength
(Jamar Plus + Digital Hand Dynamometer; Patterson
Medical, Warrenville, IL, USA). Each hand is tested
three times using the right hand first. This test was
chosen over other available fitness (e.g. 6 min walk test),
since this can be conducted irrespective of visual or
motor impairment, which is highly prevalent given at
the age range of our participants.
Measurements of AGE, anthropometry, and hand grip
strength are performed according to the protocols for
the German National Cohort [10].
Other diseases, current and recent medication intake
Previous diagnoses of other diseases are assessed at the
interview. These include liver, kidney, arthritic and skin
diseases as well as cancer and diseases of the respiratory
tract. Current and recent medication use is assessed
using IDOM software [32], directly from the pharma-
ceutical registration number, if available. Medication use
can help pinpoint a multitude of conditions such as
hyperlipidemia, hypertension, and diabetes.
We ask all participants for permission to contact their
primary physician, their ophthalmologist, and the last hos-
pital they visited. This allows for confirming and extend-
ing interview-based information on disease diagnoses. As
one of two tertiary care facilities in the recruitment area,
and the only one for Ophthalmology and Dermatology,
the University Hospital Regensburg is the hospital that
best facilitates the gathering of such information.
Biosampling and immediate laboratory analyses
Collection and procession of biosamples are conducted
following standard operation procedures developed for
this study based on established methods and recommen-
dations [33]. Deviations from these standard operation
procedures (e.g. extended sample handling at room
temperature) are recorded and linked with the biosam-
ple information. All samples are processed immediately
and are kept on dry ice before final storage at the end of
the day. Identification, assignment and link to eCRF data
for biosamples including 2D-barcoded tubes are man-
aged by self-developed integrated software. For an over-
view of biosample aliquots and storage see Table 2.
Non-fasting blood samples are drawn in a sitting pos-
ition after at least five minutes of resting. Mild venous
stasis is applied for a maximum duration of one minute.
Whole blood is taken using a 21G multifly needle
(Sarstedt, Nümbrecht, Germany) and is transferred into
four serum tubes with clot activator, five tubes contain-
ing tripotassium ethylenediaminetetraacetate (K3-EDTA)
as an anticoagulant (all Sarstedt) and one PAXgene Blood
RNA tube (PreAnalytiX, Hombrechtikon, Switzerland) with
a defined order (serum - > K3-EDTA - > PAXgene). For the
PAXgene tube, luer (BD Biosciences, Heidelberg, Germany)
and membrane adapter (Sarstedt) are applied. K3-EDTA
tubes are gently mixed after blood draw for 5 min.
One K3-EDTA and one serum tube is used for immedi-
ate analysis of blood parameters in a central laboratory
(synlab, Regensburg, Germany). From the other four K3-
EDTA tubes, a total of four aliquots à 750 μl are trans-
ferred to 2D-barcoded tubes (ABgene or Matrix, Thermo
Scientific, Hudson, NH, USA) for storage at -80 °C. For
subsequent DNA isolation, 6 aliquots à 1.5 ml are frozen
at -20 °C in 2 ml standard tubes (Sarstedt). The remaining
K3-EDTA tubes are immediately centrifuged at 2,000 g for
15 min at room temperature to separate plasma from the
cellular fraction. Supernatants are transferred to a fresh
15 ml tube (Sarstedt) and mixed carefully by pipetting
up and down. Twelve plasma aliquots à 500 μl are trans-
ferred to 2D-barcoded tubes (Thermo Scientific) for stor-
age at -80 °C. Additionally, two aliquots à 1.5 ml are
stored in sterile 2 ml cryo tubes (Sarstedt) in liquid nitro-
gen gas phase.
Serum tubes with clot activator are left in upright pos-
ition for 30 min after blood draw and are centrifuged at
2,000 g for 15 min at room temperature to separate
serum from the cellular fraction as soon as possible.
Supernatants from three serum tubes are transferred to
a fresh 15 ml tube (Sarstedt) and mixed carefully by pip-
etting up and down. Twelve serum aliquots à 500 μl are
transferred to 2D-barcoded tubes (Thermo Scientific)
for storage at -80 °C. Additionally, two samples à 1.5 ml
are stored in sterile 2 ml cryo tubes (Sarstedt) in liquid
nitrogen gas phase.
The PAXgene RNA tube is mixed ten times by turning
after blood draw and is immediately centrifuged at
2,300 g for 10 min at 4 °C. From the supernatant, two al-
iquots with 1 ml each are transferred to sterile 2 ml cryo
tubes (Sarstedt). The remaining supernatant is trans-
ferred to a fresh 15 ml tube (Sarstedt) without disturbing
the pellet. Supernatant (1 ml) is used to resolve the pel-
let in the PAXgene tube and to transfer it to a sterile
2 ml cryo tube (Sarstedt). PAXgene samples are stored
in liquid nitrogen gas phase.
Urine is sampled from midstream into a sterile 100 ml
cup with a screw cap (Sarstedt). Within 15 min, two urine
monovettes (Sarstedt) are filled and centrifuged at 2,300 g
for 10 min at 4 °C. Afterwards, 1.5 ml supernatant is
transferred to a sterile 2 ml cryo tube (Sarstedt) and stored
in liquid nitrogen gas phase. The urine in monovettes is
stored at -80 °C. During centrifugation, a Clinitek Microal-
bumin 9 reagent strip (Siemens Healthcare Diagnostics
Inc., Tarrytown, NY, USA) is applied on the remaining
urine in the cup for analysis of albumin, blood, creatinine,
glucose, ketone, leukocytes, nitrite, protein, and pH.
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Information for study participants after the study
program
Each participant who requests feedback from the results
of his/her medical examinations and standard laboratory
parameters obtains these in a written letter. If applicable,
we suggest that the participant seeks advice from his/her
general practitioner. In the case of severe abnormalities
in the examinations (i.e., life-threatening and treatable),
medical support is sought immediately, which is facili-
tated by our study center being located directly at the
University Hospital Regensburg.
Discussion
AugUR is a study platform with a focus on the elderly
population from the city and county of Regensburg,
Germany. It incorporates extensive biobanking, genotyp-
ing and a modern study protocol specifically tailored to
the conditions of the elderly. Embedded sub-studies and
measurements in biosamples using ‘–omics’ techniques
will make this platform an important resource for
research in the elderly.
What can be gained from in-depth epidemiological
data in the elderly? A cross-sectional study with partici-
pants starting at 70 years of age is usually enriched with
cases with a certain disease, and well-matched healthy
controls are available. A longitudinal study design also al-
lows for analyzing risk factors, such as the influence of life
style factors on disease development and progression, and
the interaction of non-genetic with genetic factors. The
longitudinal aspect of a study with elderly participants can
provide sufficient numbers of incident cases more quickly
than a study with younger participants.
Beyond these major objectives of studying disease
etiology, a study in the elderly has further practical us-
ability: It yields prevalence and incidence estimates for
late-onset diseases that are important determinants for
public health managers. Such estimates require high-
quality data and cannot be easily transferred across
countries due to differences in health care systems, gen-
etic background, climatic conditions, and life style. Add-
itionally, a study in the elderly can also serve as a control
group for case-control comparisons, which overcomes
many of the usual challenges of control group identifica-
tion: Control groups in genetic studies are often
enriched for other diseases, e.g. by recruiting from hos-
pitals, or are substantially younger or from a different re-
gion or even country than the patient group. Finally,
reference values of clinical diagnostic parameters in the
elderly are often lacking and warranted as most such
parameters are evaluated in ‘normal’ adults, but applied
to the patients entering the clinics – which are, mostly,
of higher age.
We need to acknowledge a limitation of our study,
which arises from the fact that only a certain proportion
of invited persons will respond and participate and that
the response will depend on health status: since all par-
ticipants are required to make their appointment by
phone and to come to the study center in-person, a cer-
tain level of mobility and hearing/cognitive ability is re-
quired that is not self-evident in that age range. Therefore,
we will recruit from the ‘mobile’ portion of the general
elderly population.
In summary, our population-based cohort study in
the elderly is a platform that will help to improve our
understanding of late-onset disease mechanisms that
may, ultimately, lead to improved prevention, diagno-
sis, and therapy.
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